⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123244 | 0.97 | — | — | |
| SCHEMBL7124637 | 0.94 | MAOA (0.32) | — | |
| SCHEMBL7115081 | 0.82 | TDP1 (0.39) | — | |
| SCHEMBL4972122 | 0.62 | GAA (0.31) | — | |
| SCHEMBL11561272 | 0.56 | MAPT (0.41) | — | |
| SCHEMBL7122745 | 0.55 | F10 (0.58) | — | |
| SCHEMBL8738128 | 0.54 | MAPT (0.54) | — | |
| SCHEMBL7242250 | 0.53 | SIGMAR1 (0.63) | — | |
| SCHEMBL28203677 | 0.53 | MAPT (0.35) | — | |
| Biphenyl SCHEMBL27929421 | 0.52 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | claimed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | claimed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |